Insider Selling: Humana Inc. (NYSE:HUM) Insider Sells 3,703 Shares of Stock

Humana Inc. (NYSE:HUM) insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Humana Trading Up 3.9 %

HUM opened at $262.47 on Monday. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $471.37. The company has a market capitalization of $31.60 billion, a P/E ratio of 23.25, a PEG ratio of 2.12 and a beta of 0.55. The stock’s fifty day moving average is $272.60 and its two-hundred day moving average is $313.45. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Analysts forecast that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.35%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s payout ratio is 31.36%.

Institutional Trading of Humana

A number of hedge funds have recently bought and sold shares of the stock. Central Pacific Bank Trust Division boosted its holdings in shares of Humana by 110.7% in the 4th quarter. Central Pacific Bank Trust Division now owns 2,950 shares of the insurance provider’s stock valued at $748,000 after buying an additional 1,550 shares in the last quarter. Everence Capital Management Inc. grew its holdings in Humana by 57.5% in the fourth quarter. Everence Capital Management Inc. now owns 5,530 shares of the insurance provider’s stock worth $1,403,000 after purchasing an additional 2,020 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Humana by 41.0% during the fourth quarter. GAMMA Investing LLC now owns 1,906 shares of the insurance provider’s stock worth $484,000 after purchasing an additional 554 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of Humana by 15.5% in the 4th quarter. Versant Capital Management Inc now owns 387 shares of the insurance provider’s stock worth $98,000 after purchasing an additional 52 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in Humana by 2.4% during the 3rd quarter. Principal Financial Group Inc. now owns 170,636 shares of the insurance provider’s stock worth $54,047,000 after buying an additional 3,961 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on HUM shares. Morgan Stanley increased their target price on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Leerink Partners cut shares of Humana from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Barclays boosted their price objective on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Finally, Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective on the stock in a research report on Tuesday, October 8th. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Humana has a consensus rating of “Hold” and a consensus target price of $300.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.